J Leray

Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort

Linda Wittkop, Juliette Bitard, Estibaliz Lazaro et al. · The Journal of Infectious Diseases · 2012 · 65 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

David L. Emerson, Raymond A. Bendele, Eric Brown et al. · PubMed · 2000 · 61 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL

Blake Tomkinson, Ray Bendele, Francis J. Giles et al. · Leukemia Research · 2003 · 39 citations

Medicine, Oncology, Pharmacology +9

Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist

Diane M. Ignar, John L. Andrews, Samuel M. Witherspoon et al. · Clinical & Experimental Metastasis · 1998 · 35 citations

Medicine, Cancer Biology, Oncology +8

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

John Desjardins, Elizabeth Abbott, David L. Emerson et al. · Anti-Cancer Drugs · 2001 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacology +14